Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
23/10/2026 18:31
BRIEF-Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week Oct 23 (Reuters) - Hansa Biopharma AB HNSA.ST:
HANSA BIOPHARMA ANNOUNCES POSITIVE IDEFIRIX PAES RESULTS PRESENTED IN THE HIGH-IMPACT CLINICAL TRIALS SESSION AT ASN KIDNEY WEEK
HANSA BIOPHARMA AB - IDEFIRIX WELL TOLERATED WITH SAFETY PROFILE CONSISTENT WITH PRIOR EXPERIENCE
HANSA BIOPHARMA AB - REPORTS 1-YEAR GRAFT SURVIVAL OF 92% AND PATIENT SURVIVAL OF 98%
Source text: ID:nWkr17gKGl
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS